A detailed history of Royce & Associates LP transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Royce & Associates LP holds 155,803 shares of ARCT stock, worth $2.57 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
155,803
Previous 131,718 18.29%
Holding current value
$2.57 Million
Previous $3.21 Million 12.75%
% of portfolio
0.03%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$18.08 - $25.38 $435,456 - $611,277
24,085 Added 18.29%
155,803 $3.62 Million
Q1 2024

May 13, 2024

BUY
$31.23 - $42.99 $58,774 - $80,907
1,882 Added 1.45%
131,718 $4.45 Million
Q2 2023

Aug 07, 2023

BUY
$23.94 - $32.36 $1.2 Million - $1.62 Million
50,000 Added 62.63%
129,836 $3.72 Million
Q2 2020

Aug 07, 2020

SELL
$12.66 - $58.27 $336,756 - $1.55 Million
-26,600 Reduced 24.99%
79,836 $3.73 Million
Q2 2019

Aug 12, 2019

BUY
$5.78 - $9.79 $615,200 - $1.04 Million
106,436 New
106,436 $1.01 Million

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $439M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.